Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Prescription for a pharmacyte.

Jeffrey A Hubbell1

  • 1Institute for Molecular Engineering, University of Chicago, Chicago, IL, USA. Materials Science Division, Argonne National Laboratory, Argonne, IL, USA. Institute for Bioengineering, School of Life Sciences and School of Engineering, Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland. jhubbell@uchicago.edu jeffrey.hubbell@epfl.ch.

Science Translational Medicine
|June 12, 2015
PubMed
Summary

T cells can deliver drug-loaded nanoparticles directly to lymphoma cells within lymph nodes. This targeted approach enhances drug efficacy compared to free drugs or nanoparticles alone.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Composite biomaterials of polyelectrolyte complex micelle nanoparticles in hyaluronic acid gels enable local, targeted miR-92a inhibition and enhanced angiogenesis in diabetic wound repair.

Journal of controlled release : official journal of the Controlled Release Society·2026
Same author

Corrigendum to 'Generation of potent cellular and humoral immunity against SARS-CoV-2 antigens via conjugation to a polymeric glyco-adjuvant' [Biomaterials, 128 (2021), 121159].

Biomaterials·2026
Same author

Serum albumin-fused interleukin-10 prevents neuroinflammation by promoting immunoregulation in the secondary lymphoid organs and limiting immune cell infiltration in the spinal cord.

bioRxiv : the preprint server for biology·2026
Same author

Precision mRNA Nanomedicine for Targeted Vascular Therapies in ARDS and Atherosclerosis.

bioRxiv : the preprint server for biology·2026
Same author

LDL-binding IL-10 reduces vascular inflammation in atherosclerotic mice.

Nature biomedical engineering·2026
Same author

Polyelectrolyte complex micelles embedded in hyaluronic acid gels enable local, targeted miR-92a inhibition to accelerate diabetic wound repair.

bioRxiv : the preprint server for biology·2025

Area of Science:

  • Immunology
  • Nanotechnology
  • Oncology

Background:

  • T cells possess natural homing capabilities to navigate biological systems.
  • Lymphoma often resides within lymph nodes, posing a challenge for conventional therapies.
  • Nanoparticle drug delivery systems offer potential for targeted treatment.

Purpose of the Study:

  • To investigate the use of T cells as carriers for drug-laden nanoparticles targeting lymphoma.
  • To evaluate the enhanced efficacy of cell-associated nanoparticle delivery compared to free nanoparticles or free drug.

Main Methods:

  • Utilizing the homing capacity of T cells for targeted delivery.
  • Associating drug-loaded nanoparticles with T cells.
  • Comparing therapeutic outcomes of T cell-delivered nanoparticles versus conventional nanoparticle and free drug formulations.

Related Experiment Videos

Main Results:

  • T cell-mediated delivery of drug-laden nanoparticles successfully targeted lymphoma cells in lymph nodes.
  • Significantly increased drug efficacy was observed with the T cell-associated nanoparticle approach.
  • Conventional nanoparticle and free drug methods showed lower efficacy in comparison.

Conclusions:

  • T cell-guided nanoparticle delivery represents a promising strategy for enhancing lymphoma treatment.
  • The efficient homing of T cells can be leveraged to improve drug delivery and therapeutic outcomes in lymphoma.
  • This approach offers a potential advantage over traditional drug delivery methods for lymph node-resident cancers.